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Packaging cell lines derived from human immunodeficiency virus-1 (HIV-1) are promising tools for in vivo somatic cell gene
therapy protocols due to the ability of lentiviruses to infect nondividing cells. We describe here the generation of a safe, stable
HIV-1 packaging cell line capable of expressing all of the HIV-1 structural, enzymatic, and regulatory proteins but lacking
majority of the cis-acting sequences. The use of an inducible expression system circumvented the cytotoxic and cytostatic
effects associated with the expression of some of the HIV-1 viral proteins. Reverse transcriptase activity was detectable in
the supernatant from the stable packaging line 1 day after induction, while vector titers peaked 5 days postinduction. Vector
titers of up to 3.5 3 104 infectious units/ml (IU/ml) were maintained through 8 months following the establishment of the cell
line. Lineage-specific gene delivery can be achieved from this established cell line as viral stocks obtained specifically infect
CD41 target cells. Moreover, this cell line provides a safe and easy to use system for screening of drugs that inhibit HIV-1
replication. © 1998 Academic Press
INTRODUCTION
A hallmark of retrovirus replication is the very efficient
integration of the viral DNA into the genome of an in-
fected cell, where it is stably maintained and transmitted
to daughter cells. This characteristic has provided impe-
tus for developing retroviral vector systems for the effi-
cient transduction and the long-term maintenance and
expression of exogenous genes in primary cells. There
are two basic components of a retroviral vector system,
the defective vector virus containing the cis-acting se-
quences required for efficient viral replication and the
packaging cell, which provides the viral proteins re-
quired in trans for viral replication. Most retroviral-based
vectors described to date have been derived from the
oncoretrovirus, murine leukemia virus (MLV) (Harris and
Lemoine, 1996; Robbins et al., 1998). While MLV-based
vectors have proven useful for ex vivo transduction, a
limitation of these systems is that proviral integration into
the host genome requires at least one round of cell
division (Miller et al., 1990). Nuclear envelope breakdown
that accompanies cell division appears to be necessary
for the nuclear import of the oncoretroviral preintegration
complex to permit the integration process (Lewis and
Emerman, 1994). In contrast, the preintegration complex
of the lentivirus human immunodeficiency virus-1 (HIV-1)
can directly traverse the nuclear envelope barrier, report-
edly due to the nuclear localizing sequences present
within the HIV-1 proteins Vpr (Heinzinger et al., 1994), MA
(Gallay et al., 1995a), and IN (Gallay et al., 1995b). This
ability to infect nondividing cells provides an incentive for
the development of HIV-1 based packaging cell systems
for use with in vivo gene therapy. Additionally, HIV-1
packaging lines would also be valuable for studies of
lentiviral biology. For example, such cell lines allow one
to establish assays that can be utilized to study HIV-1
replication, mutation frequencies, and latency (Yu et al.,
1997). Moreover, inducible packaging cells provide a
safe system for drug screening since viral proteins are
not produced until induction and biologically hazardous
wild-type virus is never generated.
Recently several reports detailing gene transfer into
nondividing cells using lentiviral shuttle vectors have
been described (Naldini et al., 1996a,b; Aiken, 1997; Bartz
and Vodicka, 1997; Blo¨mer et al., 1997). However, most
employ transient protocols to produce the vector stocks,
which can vary greatly with each transfection, and have
the potential for untoward homologous and nonhomolo-
gous recombination events. These drawbacks with tran-
sient transfection procedures limit their application in
basic and clinical research.
Most of the transient protocols published to date de-
scribe the generation of HIV-1 particles pseudotyped
with a heterologous envelope, the vesicular stomatitis
virus G protein, VSV-G (Naldini et al., 1996a,b; Blomer et
al., 1997). The use of VSV-G has helped to bolster titers to
levels which are desirable for efficient gene transfer into
primary cells but concomitantly results in loss of target
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cell specificity. Stable HIV-1 packaging lines which main-
tain the target cell tropism afforded by the HIV-1 enve-
lope would have the potential to more reproducibly yield
lineage-specific viral stocks capable of infecting nondi-
viding cells. HIV-1-based vectors may be particularly
useful in the treatment of HIV-1 infection, as the antiviral
exogenous gene would be specifically targeted to the
HIV-1 host cells. Moreover, the vector virus could also be
rescued in vivo by the patients’ wild-type virions, and
thus comparatively lower titers of the therapeutic vector
may be permissible as in vivo amplification is possible
(Poeschla et al., 1996).
Several biological features of HIV-1 make it challeng-
ing to successfully develop a safe, efficient HIV-1-based
packaging line. First, the pathogenicity associated with
the virus requires that the viral stocks be completely void
of any replication competent virus. Also HIV-1 expresses
several accessory proteins reported to enhance high-
level infection/replication, and it would therefore be de-
sirable to include them in the packaging cell line (Hein-
zinger et al., 1994). However, a technical hurdle exists in
that several of the trans-acting proteins, including Env
(Sodroski et al., 1986), Pro (Kaplan and Swanstrom, 1991),
and Vpr (Bartz et al., 1996) have been reported to be
cytotoxic or cytostatic, hampering the establishment of a
constitutively expressing packaging cell line.
Extending upon previous work by our laboratory in
which a tetracycline inducible system was employed to
establish a HIV-1 packaging cell line (Yu et al., 1996), this
paper reports the creation of an additional inducible cell
line which, unlike the previous producer line, is capable
of expressing all the regulatory proteins of HIV-1. Appli-
cation of this line should lend greater authenticity to
studies of HIV-1 biology (i.e., replication, recombination,
latency, etc.) as all viral proteins are present, and hence
this system mimics an in vivo HIV-1 infection more
closely. To achieve a higher degree of safety, the pack-
aging line described herein also lacks most of the 59
encapsidation sequences as well as the 59LTR and part
of the 39LTR. Transduction titers of up to 3.5 3 104 IU/ml
are reported.
RESULTS
Design of the tetracycline-inducible HIV-1 packaging
cell line
Packaging cell lines are engineered to produce the
trans-acting viral proteins. In our packaging cell line
system, the expression of the trans-acting HIV-1 proteins
is tightly regulated by two levels of induction. First, the
early gene products, including Rev and Tat, are ex-
pressed from an inducible promoter consisting of the
heptamerized tetracycline operator (tetO) sequences
from Escherichia coli coupled to a minimal CMV pro-
moter (Gossen and Bujard, 1992). Transcription from this
promoter is upregulated only in the presence of the
transactivator, tTA, a fusion protein between the tetracy-
cline repressor and the activation domain of the herpes
simplex virus VP16 protein. When present, tetracycline
binds to the tTA protein, resulting in allosteric changes in
the transactivator such that it cannot bind to the tetO
sequences, resulting in a suppression of viral protein
expression. In the absence of tetracycline, tTA can bind
to and transactivate the inducible promoter, leading to
expression of downstream genes. Although transcription
of all the HIV-1 genes is controlled by this promoter in our
system (Fig. 1), the translation of the late gene products
is possible only after Rev is produced, since the nuclear
export of the singly spliced and unspliced RNA encoding
these proteins is possible only in its presence. This
results in two levels of induction, as expression of the
late gene products, which include Gag, Pol, Env, Vpr,
Vpu, and Vif, is possible only after expression of Rev,
which is in turn dependent upon the absence of tetracy-
cline.
To address safety concerns, the inducible packaging
cell lines were generated by separating the gag-pol and
env genes by splitting expression from two different
recombinants. Additionally, rev expression was placed
on the env-containing construct, effectively separating it
from the tat gene (Fig. 1). Furthermore, the two expres-
sion plasmids were sequentially transfected into the
packaging cell to reduce the possibility of recombination
resulting in production of replication-competent virus
(Markowitz et al., 1988).
FIG. 1. HIV-1 packaging cell constructs and vectors. Boxes inter-
rupted with jagged line symbolize partial deletions; DC signifies a
33-bp deletion downstream of the splice donor site (nucleotide 295–
328), which deletes at least part of the encapsidation signal; tetO,
heptamerized tetracycline operator fused with a minimal CMV pro-
moter (Gossen and Bujard, 1992); SV40 pA, SV40 polyadenylation
signal; puro, puromycin gene; SNV spleen necrosis virus U3 promoter;
gfp, green fluorescent protein gene; IRES, internal ribosomal entry site
from encephalomyocardiis virus (EMCV) 59 nontranslated region (NTR)
(Koo et al., 1992).
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Establishment of the HIV-1 packaging cell line
The generation of the parental Env-inducible cell line
#69 has been described previously (Yu et al., 1996).
Briefly, pTIRevEnv was cotransfected along with the
marker plasmid pHMR272 (Bernard et al., 1985), express-
ing the hygromycin resistance gene, into HtTA-1 cells, a
HeLa-based cell line that constitutively expresses the
fusion protein tTA (Gossen and Bujard, 1992), and a
stably transfected cell clone designated #69 was ob-
tained (Yu et al., 1996). #69 cells were then cotransfected
with the ptet-HIV-gp (Fig. 1) and pSV2gpt constructs and
selected for resistance to GPT (Mulligan and Berg, 1981).
Sixty-eight clones were expanded and screened by fu-
sion and reverse transcription assays. HeLa-CD4-LTR-
bgal cells were used for the fusion assay (Kimpton and
Emerman, 1992). These cells fuse with HIV-1 Env-ex-
pressing cells because they bear CD4 on their cell sur-
face. HeLa-CD4-LTR-bgal also harbors a vector encod-
ing the lacZ gene driven by the HIV-1 59LTR; in the
presence of the viral protein Tat, this promoter is trans-
activated leading to the expression of lacZ. By coculti-
vating HeLa-CD4-LTR-bgal with a putative packaging
line, the expression of Tat can be ascertained in the line
by staining the fused cells with Xgal. Thus this fusion
assay screens for expression of proteins from plasmids,
pTIRevEnv and ptet-HIV-gp in the cell. Ten clones posi-
tive for both fusion and RT activity were further charac-
terized.
Inducible viral protein expression
To ensure that the viral proteins are expressed only
upon the removal of tetracycline, the levels of the enve-
lope glycoprotein, gp120, and matrix protein, p24 were
tested prior to and after induction. Western blots are
shown using total cell lysate from one of the clones
selected, designated B16, before induction, and on Days
1–7 after induction (Figs. 2A and 2B). Neither protein was
detectable before induction, but positive bands were
clearly visible 5 days after induction. However, reverse
transcriptase activity was detectable 1 day postinduc-
tion, with no activity detectable before induction (Fig. 3).
One possibility to explain why gp120 and p24 were not
detectable in cell lysates until 5 days postinduction in
comparison to 1 day for the reverse transcriptase activity
is that the latter is an enzymatic assay, which is more
sensitive than Western blots. The sensitivity of the West-
ern blots is also dependent on the quality of the antibod-
ies used for detection.
Transduction titers of packaging cell line
The HIV-1-derived vector pHVP (Richardson et al.,
1993) was used to test the ability of cell lines to propa-
gate vector virus (Fig. 1). Mass populations of the 10
packaging cell lines each stably transfected with pHVP
were obtained by selection with puromycin. The cells
were then induced by tetracycline withdrawal, and su-
pernatant was harvested each day for a week and used
to inoculate HeLaT4 target cells. The target cells were
placed under puromycin selection 24 h postinfection,
and titers were calculated by counting the number of
puro-resistant colonies 2 weeks later. Different lines
gave peak titers on different days postinduction. Highest
titers were obtained from two different lines, B16 and
D11. pHVP-transfected B16 cells (B16HVP) yielded peak
titers 5 days postinduction, ranging from 1.0 3 103 to
1.5 3 103 IU/ml (Table 1), while pHVP-transfected D11
cells yielded peak titers 4 days postinduction, ranging
from 0.6 3 103 to 2.0 3 103 IU/ml. However, because the
level of gp120 expression by clone D11 as detected by
Western blots was comparatively low, B16 was chosen
for further analysis.
Southern blotting was employed to confirm that the
infected target cells contained the transduced vector.
This was done by extracting genomic DNA from individ-
ually expanded puro-resistant HeLaT4 cells, which had
been infected with viral stocks from B16HVP cells, and
subjecting the DNA to Southern blotting. The blots were
probed with a portion of the gag gene to detect a 2.2-kb
fragment of the transduced vector (Fig. 4A); all progeny
cell clones were verified to contain the vector provirus
(Fig. 4B).
Transduction titers of clone B16 were confirmed with
another HIV-1-based vector pHSGIP (Fig. 1). Harvested
FIG. 2. Western blotting to analyze inducible expression of gp120 (A)
and p24 (B). Total cell protein from the B16 cell line was extracted on
Day 0 prior to induction and on Days 1–7 postinduction and used for
Western blotting as described in Materials and Methods. 1, cell lysate
from HeLaT4 cells infected with wild-type HIV-1; 2, cell lysate from
uninfected HeLaT4 cells.
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supernatant from pHSGIP transfected B16 cells
(B16HSGIP) was used to infect target cells and titers
scored by counting puromycin resistant colonies. These
titers were also confirmed by counting the number of
green fluorescent target cells clones. Stable B16HSGIP
cells yielded titers ranging from 0.5 3 103 to 0.7 3 103
(Table 1). However, titers ranging from 2.0 3 104 to 3.5 3
104 IU/ml were obtained from a clone designated
#2B16GIP, which was obtained by subcloning from the
mass population of B16HIV-GIP cells (Table 1). Sub-
clones often provide higher titers than the mass popula-
tions as they are representative of a homogenous set of
cells.
Supernatant samples collected from clones B16HVP
and #2B16GIP were also assayed for the presence of
replication-competent virus as described previously (Yu
et al., 1996). Briefly, H9 cells were inoculated with the
supernatant collected on Day 5 postinduction from the
packaging lines, and cultured continually for 30 days.
Culture supernatant from the inoculated H9 cells were
collected periodically over 30 days, and on the 30th day
used to inoculate fresh H9 cells. Supernatant from the
freshly inoculated cells was collected 5 days later and,
along with the previously collected supernatant samples,
assayed for the presence of p24gag via ELISA. The levels
of the antigen in the supernatant samples were indistin-
guishable from the background levels. The original su-
pernatant from clone B16 used to inoculate the H9 cells
and purified p24gag antigen were used as positive con-
trols. The results confirmed that under the assay condi-
tions used, the packaging cell line B16 did not produce
detectable levels of replication-competent virus.
DISCUSSION
This report describes the establishment of an induc-
ible, safe, and stable HIV-1 packaging cell line, B16.
Expression of all viral proteins is tightly regulated in B16
under the control of a tetracycline-responsive promoter.
B16 was determined to have transduction titers of 2.9 6
0.8 3 104 IU/ml and not produce replication competent
virus at detectable levels.
The packaging line, B16, completely lacks all viral
sequences located upstream of nucleotide 253 of the
HIV-1 genomic RNA, including the 59 LTR and the primer
binding site (pbs); part of the 39 LTR has also been
excluded. In addition, the gag-pol construct, ptetHIV-gp
has a deletion between the 59 major splice donor site
and the gag initiation codon (nucleotides 295–328) which
corresponds to a predicted stem-loop structure report-
TABLE 1
Transduction Titers from Packaging Cell Line B16
Day
Titer (IU/ml)a
B16HVP B16HIV-GIP #2B16GIP
1 1.0 3 101 ND ND
2 1.6 3 101 ND ND
3 3.0 3 101 ND 5.0 3 102
4 3.5 3 102 ND 1.6 3 103
5 1.2 6 0.3 3 103 0.6 6 0.1 3 103 2.9 6 0.8 3 104
6 1.5 3 103 ND 1.1 6 0.5 3 104
7 1.1 6 0.4 3 103 0.2 6 0.1 3 103 0.5 6 0.2 3 104
a Vector virus titers were determined by infecting HeLaT4 cells as
described in Materials and Methods. Where standard deviations are
reported, results represent average titers from three separate experi-
ments. Otherwise, titers reported are from a single experiment. ND, not
determined.
FIG. 3. Reverse transcriptase assay. Supernatant from B16 cells
transfected with pHVP or pHIV-GIP was harvested on Day 0 prior to
induction and on Days 1–7 postinduction and assayed for reverse
transcriptase activity as described in Materials and Methods.
FIG. 4. Southern analysis for target cell transduction. Genomic DNA
samples from individual HelaT4 target cell clones, designated T1, T2,
T3, T4, and T5 which had been infected with supernatant from pHVP-
transfected B16 cells were digested with SacI (S), and subjected to
Southern analysis. (A) Diagram of HIV-1 vector pHVP indicating the
probe used from the gag region that detects a specific 2.2-kb fragment
from SacI digested proviruses. (B) Southern blot showing diagnostic
band of 2.2-kb band in all five clones. 1, SacI-digested pHVP plasmid;
2, genomic DNA from uninfected HeLaT4 cells.
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edly critical for RNA encapsidation (McBride and Panga-
niban, 1996). The combination of these deletions results
in a lentiviral packaging cell line that lacks the majority of
the cis-acting sequences considered important for HIV-1
virion packaging. Expression of HIV-1 proteins from two
vectors, pTIRevEnv and ptet-HIV-gp, introduced sequen-
tially affords an additional tier of safety by greatly reduc-
ing the probability of recombination during transfection
which could contribute to the emergence of replication
competent virus.
Additionally, ptet-HIV-gp contains open reading frames
for all HIV-1 accessory proteins. As the biological roles of
the HIV-1 regulatory proteins have yet to be defined
precisely, this line may prove useful in protein function
investigations. Furthermore, as B16 is a HeLa-based cell
line, it does not express the HIV-1 Env receptor, CD4.
Therefore the producer cell line cannot be infected with
the vector virus it generates, and so there is no cycling of
the vector virus once it is produced. Thus an assay
involving a single cycle of replication of vector virus from
producer cells to target cells can be established and be
utilized for studies of HIV-1 mutation and recombination
rates (Yu et al., 1997). The packaging line also provides a
model system to explore other aspects of HIV-1 biology
including HIV-1 replication and latency.
Currently, the more common methods used for screen-
ing of anti-HIV-1 drugs in vitro is by detecting p24 HIV-1
core antigen production by infected cells or by HeLa-
CD4 plaque assays (Gervaix et al., 1997). Monitoring
inhibitory effects of drugs to HIV-1 replication by these
methods requires multiple manipulations and can be
time consuming. The B16 packaging cell line can be
used to investigate anti-HIV-1 drug susceptibility. A de-
cline in viral titers by the action of putative therapeutic
anti-HIV-1 drugs can be rapidly ascertained within 48 h
by the use of a GFP-encoding vector such as pHSGIP. By
performing the assay in 96-well plates, multiple drugs
can be screened at a range of concentrations. As all the
viral proteins in HIV-1 infected patients are present in
this line, the antiviral activity of a potential drug can be
accurately tested. Studies to examine such drugs have
already been initiated in our laboratory (M.K. and J.D.,
unpublished data). Hence this packaging line provides a
fast, easy, inexpensive, and safe system to screen for
antiviral drugs.
Two groups have previously reported the construc-
tion of constitutive HIV-1 packaging cell lines with
titers ranging from 103 to 105 IU/ml (Corbeau et al.,
1996; Poeschla et al., 1996; Srinivasakumar et al.,
1997). However, it is unclear whether or not these cell
lines express all of the accessory proteins. For in-
stance, as mentioned earlier, Vpr has cytostatic prop-
erties in a variety of cell types (Bartz et al., 1996), and
in a constitutively expressing HIV-1 packaging cell
line, the level of Vpr would therefore be expectedly low
or nonexistent. This might not be reflected in titers
obtained with dividing cells but would perhaps
dampen titers on nondividing cells, as Vpr has been
implicated in conferring upon HIV-1 the ability to infect
nondividing cells (Heinzinger et al., 1994). It is possi-
ble, nevertheless, that proteins expressed specifically
from the strains of HIV-1 which were used in these
lines (HIV-1 MN and HIV-1 NL4-3) have different levels
of toxicity. The inducible system we adopted for the
packaging line described in this manuscript would
circumvent the toxicity associated with constitutive
expression of HIV-1 proteins and may have the addi-
tional advantage of synchronizing viral protein expres-
sion.
Transient HIV-1 packaging lines which produce HIV-1
particles pseudotyped with a heterologous envelope pro-
tein, VSV-G, have also been recently described (Naldini
et al., 1996a,b; Blomer et al., 1997). Forming VSV-G
pseudotyped vector virus presents the significant advan-
tage for gene therapeutics of yielding high-titer viral
stocks, as this envelope is less sensitive to concentra-
tion of the stocks by ultracentrifugation. However, even
though VSV-G allows for concentration without apprecia-
ble loss of infectivity, the target cell tropism of VSV-G is
too broad for many gene therapy applications. The use of
the HIV-1 envelope permits specific targeting of cells in
the CD41 compartment. This would be especially useful
in HIV-1-directed gene therapy, as the antiviral genes
would be targeted to HIV-1-infected or -infectible host
cells. The titers achieved by our line are too low for
efficient in vivo gene transfer, and attempts are under-
way currently in the laboratory to boost titers. However,
an increase in transgene dispersal may be possible
utilizing low titers as HIV-1-based vectors could be res-
cued in vivo in infected patients by their wild-type virions
and thus spread to a larger pool of target cells. The use
of HIV-1 vectors to target viral RNA of infected cells with
genes such as antisense RNAs and ribozymes ensures
the intracellular colocalization of target and effector mol-
ecules. Inducible expression of an antiviral gene (e.g.,
suicide gene) may also be achieved by exploiting the
dependence of HIV-1 gene expression upon the regula-
tory proteins Tat and Rev.
The generation of the B16 cell line is an advancement
toward the development of lentiviral-based vectors for
gene therapy. Although titers presently achievable of
HIV-1 vectors in conjunction with the HIV-1 envelope are
still 10-to 100-fold lower than those obtained with the
murine retroviral systems, further improvement of the
HIV-1 systems is desirable as the usefulness of the
murine-based systems for in vivo therapy is limited. Apart
from its application in HIV-1 gene therapy, the vector
virus from a HIV-1 packaging line has the potential to
transduce nondividing CD41 lymphocytes, monocytes/
macrophages, and glial cells in vivo. Long-term expres-
sion of a therapeutic gene in the heamatopoietic com-
partment might thus be achieved.
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MATERIALS AND METHODS
Plasmid construction
Plasmid ptet-HIV-gp was constructed from a proviral
clone of the LAI strain of HIV-1 containing deletions in
the encapsidation sequences from nucleotides 241–253
and 295–328, a gift from Dr. Julian J. O’Rear, UMDNJ-
Robert Wood Johnson Medical School (numbers corre-
spond to viral RNA nucleotide sequence) (Kim et al.,
1994). A BglII deletion between 6630 and 7215, prevent-
ing expression of the env gene, and a BamHI-SspI dele-
tion between 8068 and 8200, mutating the rev gene, were
introduced; the entire segment initiating from the BssHII
site (256) to the SacI site (9170) was moved under
the transcriptional control of tetracycline-responsive in-
ducible promoter between the EcoRI/BamHI sites in
pUHD10-3 (Gossen and Bujard, 1992). Thus ptet-HIV-gp
contains open reading frames for Gag, Pol, Tat, Vpr, Vpu,
Vif, and Nef but has mutations, deletions, or disruptions
for the packaging signal (c), primer binding site (pbs),
Rev, Env, and the 59 and 39 LTRs. pTIRevEnv and pHVP
have been described previously (Richardson et al., 1993;
Yu et al., 1996). The HIV-1 based retrovirus vector pHIV-
GIP was constructed as follows: (1) a 5.8-kb deletion
(961–6854) was created in the provirus clone pLAI3 (a gift
from Dr. Michael Emerman) to generate pDLAI3; (2) the
spleen necrosis virus (SNV) U3 promoter (Emerman and
Temin, 1984) was inserted into pDLAI3 at the XhoI site;
and (3) the green fluorescent protein gene (gfp) linked to
the puromycin resistance gene (puro) via an internal
ribosomal entry site (IRES) was obtained as a cassette
(the GFP-IRES-puro cassette) from a modified version of
pJZ442, a gift from Dr Jiayou Zhang, by double digestion
with BamHI and NheI and placed under the transcrip-
tional control of SNV U3 promoter (Koo et al., 1992;
Chalfie et al., 1994). Further cloning details are available
upon request.
Cell culture and generation of the packaging cell line
HeLa cells (Jones et al., 1971) and 293T (DuBridge et
al., 1987) cells were grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS). The HeLaT4 cell line was a gift from
Dr. Michael Emerman and was grown in DMEM supple-
mented with 10% FBS and 100 mg/ml of hygromycin.
HeLa-CD4-LTR-bgal cells were obtained through the
AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIAID, NIH, from Dr. Michael Emerman
(Kimpton and Emerman, 1992) and were grown in DMEM
supplemented with 10% FBS, 100 mg/ml hygromycin, and
200 mg/ml G418. The inducible cell line #69 expressing
Env and Rev (Yu et al., 1996) was grown in DMEM with
10% FBS, 100 mg/ml hygromycin, 200 mg/ml G418, and 2
mg/ml tetracycline.
To establish the inducible packaging cell line, #69
cells (Yu et al., 1996) were cotransfected via the modified
calcium phosphate precipitation method (Gorman, 1985)
with 20 mg of ptet-HIV-gp and 0.1 mg of pSV2gpt, which
expresses the Escherichia coli xanthine-guanine phos-
phoribosyltransferase gene, gpt (Mulligan and Berg,
1981). Transfected cells were selected for resistance to
GPT (250 mg/ml xanthine, 15 mg/ml hypoxanthine, and 7
mg/ml mycophenolic acid) in the presence of tetracycline
(2 mg/ml). Individual colonies were screened for HIV-1
Tat protein expression by fusion assay as follows. Cells
were cocultivated with HeLa-CD4-LTR-bgal cells (Kimp-
ton and Emerman, 1992) at a 1:1 ratio, with 2 3 104 total
cells per well in a 24-well plate with or without tetracy-
cline for 4 days, followed by X-gal staining (Kimpton and
Emerman, 1992) and microscopic inspection to identify
blue syncytia. Supernatant was collected during this time
to assay for reverse transcriptase (RT) activity, which was
carried out according to standard protocol (Willey et al.,
1988). Cell clones which exhibited blue syncytia with
HeLa-CD4-LTR-bgal cells and were positive for RT activ-
ity upon induction were further analyzed.
Western blotting to test for inducible HIV-1
protein expression
Western blotting was employed to assay the putative
packaging cells for inducible gag and env expression.
Samples of the packaging cells were collected prior to,
and on Days 1–7 after induction. Total cell protein was
obtained by lysing the cells in buffer containing 20 mM
Tris (pH 7.4), 5 mM MgCl2, 0.1 M NaCl, 1% NP-40, 0.5%
sodium dodecyl sulfate, and 1% aprotinin. Protein con-
centrations were determined using the BCA protein as-
say reagent (Pierce, Rockford, IL) as described by the
manufacturer. Total cellular protein (100 mg) from each
sample was denatured, separated through either 7.5 or
15% SDS–polyacrylamide gels, and blotted onto polyvi-
nylidene difluoride membrane (Dupont, Boston, MA). Af-
ter blocking with 5% nonfat dry milk (Bio-Rad) in TBS-T
[150 mM NaCl, 50 mM Tris (pH 7.4), 0.05% Tween 20]
overnight at 4°C, the blots were incubated with sheep
polyclonal anti-gp120 antiserum (Hatch et al., 1992; Page
et al., 1992) or sheep polyclonal anti-p24 antiserum
(Karacostas et al., 1989) for 1 h at 1:50,000 or 1:1000
dilutions, respectively. Both antisera were obtained
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH from Dr. Michael
Phelan. Unbound antiserum was removed from the blots
by washing three times with TBS-T. Bound antiserum
was treated with peroxidase-conjugated donkey anti-
sheep antibody (Jackson ImmunoResearch Laboratories,
Inc.) at a 1:50,000 dilution for 1 h at room temperature.
The membranes were again washed three times with
TBS-T, and bound conjugated antiserum was detected by
using the Renaissance chemiluminescence reagent as
described by the manufacturer (NEN, Dupont).
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Virus production and infection
pHVP (20 mg) was stably introduced into the putative
packaging cells by the modified calcium phosphate pre-
cipitation method (Gorman, 1985), followed by selection
with 1.0 mg/ml puromycin in the presence of 2 mg/ml
tetracycline. To test the packaging capability, the cells
containing pHVP vector were seeded at 1 3 106 cells per
100 mm dish in media containing tetracycline (2 mg/ml)
and were induced by withdrawal of tetracycline 24 h after
seeding. Supernatant was harvested on Days 1–7 after
induction, and titers were determined by the infection of
HeLaT4 cells. HeLaT4 cells (3 3 105) were first treated
with 2 mg/ml of Polybrene for 30 min, followed by inoc-
ulation with 0.3 ml of supernatant at 10-fold serial dilu-
tions for 2 h. Transduced cells were selected for puro-
mycin resistance (1.0 mg/ml) 24 h postinoculation. The
pHIV-GIP vector was tested similarly. Additionally, the
titers obtained from pHSGIP were confirmed by counting
the number of green fluorescent target cells visualized
with a fluorescent microscope.
To assay for replication-competent virus, supernatant
from the putative packaging cells was harvested on Day
5 after induction and used to inoculate H9 cells. H9 cells
(2 3 106) were first treated with 2 mg/ml of Polybrene for
30 min, followed by inoculation with 0.5 ml of supernatant
for 2 h. Inoculated H9 cells were continually cultured for
30 days. Supernatant samples were collected periodi-
cally, and on the 30th day used to inoculate fresh H9
cells, from which supernatant was collected 5 days later.
Presence of p24gag antigen was assayed in all the su-
pernatant samples collected using HIV-1 p24 ELISA kit
as described by the manufacturer (Dupont).
Southern blotting
Isolation of genomic DNA and Southern blotting anal-
ysis was performed according to standard procedures
(Sambrook et al., 1989). Genomic DNA (20 mg) was di-
gested with SacI and electrophoresed through a 0.8%
agarose gel. Following genomic DNA transfer to a nylon
membrane, the blots were probed with a 32P-labeled
788-bp fragment of amplified DNA (corresponding to
nucleotide 1261–2049 of HIV-1 RNA genome) which was
obtained via polymerase chain reaction from the gag
gene from pHIV-gpt (Yu et al., 1996) (Fig. 4A).
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